ClinicalTrials.gg
CompletedNCT03399214Updated Aug 17, 2018

Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects

A Phase 1 interventional study of IOP Injection in Magnetic Resonance Imaging, sponsored by MegaPro Biomedical Co. Ltd.. Completed at 1 site in Taiwan. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-17.

Sponsored by MegaPro Biomedical Co. Ltd. · Phase 1, Interventional, and Diagnostic

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

The objective of the study is to assess the dose dependent changes in MRI signal intensity (SI) in liver after IOP Injection intravenous administration in healthy volunteers.

Read the detailed description

Find the max. signal change after IOP administration

02

Conditions studied

  • Magnetic Resonance Imaging
03

In context

Lead sponsor

MegaPro Biomedical Co. Ltd. is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, age ≥ 20 \~40 years, =18\~27.
  2. The biochemistry test results, complete blood count (CBC) test results, urinalysis test results, coagulation time test results must within normal range or considered clinically normal by the clinical investigator at screening.
  3. Male subjects must take reliable method(s) during and after the study for a period of 14 days.
  4. No screening of drug or alcohol abuse within one year prior to study enrollment.
  5. Subjects are willing to comply with the protocol and sign form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects have serious allergic history or known allergy to MRI contrast agent.
  2. Subjects with , , .
  3. Imaging and/or functional abnormalities of liver and/or spleen.
  4. Subjects have alcohol or caffeine consumption within 48 hours prior to the administration of study contrast agent.
  5. Subjects have electronically, magnetically and mechanically activated implanted devices.
  6. Subjects have participated in other trials or receive any contrast agents within 28 days prior to study enrollment.
  7. Subjects with active systemic infections, active and cardiac diseases, active gastrointestinal ulcers, or medical conditions that may significantly affect action, adequate absorption and elimination of investigational contrast agent.
  8. Subjects have taken any food 6 hours prior to administration.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    IOP Injection, Phase 1b, Cohort 1

    IV injection, 0.27 mg/kg

    Drug: IOP Injection

  • Experimental
    IOP Injection, Phase 1b, Cohort 2

    IV injection, 0.54 mg/kg

    Drug: IOP Injection

Interventions

  • DrugIOP Injection

    T1 and T2

06

What researchers measure

Primary outcomes

  1. The Change of MRI SI (%) in vessels, liver, and spleen

    The optimal imaging time of IOP injection for the maximum SI (%)

    Time frame: Day1: within 60 mins after IOP administration

Secondary outcomes

  1. The changes from baseline in hematology data

    Complete blood count and differential count, Reticulocyte count

    Time frame: within 14 days

  2. The incidence of all treatment-related adverse events (TRAE)

    Time frame: within 14 days

07

Study locations

1 site
  • Taipei Veterans General Hospital
    Taipei county, 112, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in May 2018, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2018
First posted
Jan 16, 2018
StartActual
Apr 1, 2018
Primary completionActual
May 1, 2018
CompletionActual
Jul 31, 2018
Last update
Aug 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03399214
Lead sponsor
MegaPro Biomedical Co. Ltd.
Responsible party
Sponsor
First posted
Jan 16, 2018
Start date
Apr 1, 2018
Primary completion
May 1, 2018
Completion
Jul 31, 2018
Last update
Aug 17, 2018

Study contacts

Rheun-Chuan Lee, MD
principal investigator · rclee@vghtpe.gov.tw

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion